EA201200937A1 - Твердая лекарственная форма тикагрелора - Google Patents
Твердая лекарственная форма тикагрелораInfo
- Publication number
- EA201200937A1 EA201200937A1 EA201200937A EA201200937A EA201200937A1 EA 201200937 A1 EA201200937 A1 EA 201200937A1 EA 201200937 A EA201200937 A EA 201200937A EA 201200937 A EA201200937 A EA 201200937A EA 201200937 A1 EA201200937 A1 EA 201200937A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ticagrelor
- solid medicine
- medicine form
- particles
- preparation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T428/00—Stock material or miscellaneous articles
- Y10T428/29—Coated or structually defined flake, particle, cell, strand, strand portion, rod, filament, macroscopic fiber or mass thereof
- Y10T428/2982—Particulate matter [e.g., sphere, flake, etc.]
Abstract
В изобретении описаны твердая лекарственная форма, содержащая тикагрелор в качестве фармацевтически активного ингредиента, частицы тикагрелора определенного размера, а также способы их получения.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09180628 | 2009-12-23 | ||
PCT/EP2010/070268 WO2011076749A2 (en) | 2009-12-23 | 2010-12-20 | Solid pharmaceutical dosage form |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201200937A1 true EA201200937A1 (ru) | 2013-02-28 |
EA026094B1 EA026094B1 (ru) | 2017-03-31 |
Family
ID=43778442
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201200937A EA026094B1 (ru) | 2009-12-23 | 2010-12-20 | Твердая лекарственная форма тикагрелора |
Country Status (6)
Country | Link |
---|---|
US (2) | US8663661B2 (ru) |
EP (2) | EP2515871B1 (ru) |
CA (1) | CA2785487C (ru) |
EA (1) | EA026094B1 (ru) |
ES (2) | ES2548845T3 (ru) |
WO (1) | WO2011076749A2 (ru) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102657629B (zh) * | 2012-05-14 | 2014-04-02 | 深圳市华力康生物医药有限公司 | 替卡格雷缓释片系统及其制备方法 |
CZ2012705A3 (cs) * | 2012-10-16 | 2014-04-23 | Zentiva, K.S. | Pevná orální farmaceutická formulace obsahující ticagrelor |
WO2014118808A2 (en) * | 2013-02-04 | 2014-08-07 | Hetero Research Foundation | Ticagrelor solid dispersion |
WO2014170026A1 (en) | 2013-04-18 | 2014-10-23 | Zentiva, K.S. | Stabilized amorphous ticagrelor |
EP2813216A1 (en) | 2013-06-10 | 2014-12-17 | Zentiva, a.s. | Stabilized amorphous ticagrelor |
CN105377240A (zh) * | 2013-05-29 | 2016-03-02 | 拉蒂奥法姆有限责任公司 | 固体药物剂型 |
EP2813212A1 (en) * | 2013-06-10 | 2014-12-17 | Zentiva, a.s. | Drug formulation using API in nanofibers |
EP2816043A1 (en) * | 2013-06-21 | 2014-12-24 | LEK Pharmaceuticals d.d. | Spherical ticagrelor particles |
WO2015001489A1 (en) | 2013-07-01 | 2015-01-08 | Ranbaxy Laboratories Limited | Pharmaceutical compositions of ticagrelor |
CN104414989B (zh) * | 2013-09-10 | 2019-02-22 | 四川海思科制药有限公司 | 一种替卡格雷药物组合物及其制备方法 |
CN104434805B (zh) * | 2013-09-22 | 2017-09-29 | 成都盛迪医药有限公司 | 一种替格瑞洛固体分散体及其制备方法 |
CZ2013866A3 (cs) | 2013-11-08 | 2015-05-20 | Zentiva, K.S. | Způsob výroby a nová krystalická forma intermediátu syntézy ticagreloru |
CN104644604A (zh) * | 2013-11-23 | 2015-05-27 | 天津市汉康医药生物技术有限公司 | 替格瑞洛倍半水合物胶囊及其制备方法 |
CN103751109A (zh) * | 2013-12-31 | 2014-04-30 | 北京万全德众医药生物技术有限公司 | 替格瑞洛干混悬剂及其制备方法 |
WO2015110952A1 (en) * | 2014-01-21 | 2015-07-30 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof |
CN104971042B (zh) * | 2014-04-04 | 2018-01-05 | 中国医学科学院医药生物技术研究所 | 替格瑞洛口服自微乳组合物 |
KR20160012706A (ko) * | 2014-07-25 | 2016-02-03 | 동아에스티 주식회사 | 서방성 제제 |
CN104523640B (zh) * | 2014-12-19 | 2017-02-22 | 河南润弘制药股份有限公司 | 一种替格瑞洛片及其制备方法 |
JP6451310B2 (ja) * | 2014-12-24 | 2019-01-16 | ライオン株式会社 | 固形医薬組成物及びその製造方法 |
CN105832683A (zh) * | 2015-01-15 | 2016-08-10 | 成都国弘医药有限公司 | 一种含有替格瑞洛的片剂 |
CN105998026B (zh) * | 2015-03-26 | 2020-07-14 | 四川海思科制药有限公司 | 一种替卡格雷药物组合物及其制备方法 |
TR201601835A2 (tr) | 2016-02-12 | 2017-08-21 | Ali Raif Ilac Sanayi Ve Ticaret Anonim Sirketi | Ti̇kagrelor i̇çeren formülasyonlar i̇çi̇n üreti̇m yöntemi̇ |
US20170296666A1 (en) | 2016-04-18 | 2017-10-19 | Amneal Pharmaceuticals Company Gmbh | Stable Pharmaceutical Composition Of Amorphous Ticagrelor |
CN105943515A (zh) * | 2016-06-24 | 2016-09-21 | 山东鲁抗医药股份有限公司 | 一种替格瑞洛口腔崩解片及其制备方法 |
TR201617983A2 (tr) | 2016-12-07 | 2018-06-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Ti̇cagrelorun kati oral farmasöti̇k bi̇leşi̇mleri̇ |
CN106727378A (zh) * | 2016-12-28 | 2017-05-31 | 江苏飞马药业有限公司 | 一种含有替格瑞洛主药的片剂组合物及其制备方法 |
WO2019170244A1 (en) | 2018-03-08 | 2019-09-12 | Pharmaceutical Oriented Services Ltd. | Ticagrelor—containing tablet formulation |
EA202190328A1 (ru) | 2018-07-27 | 2021-07-01 | КРКА, д.д., НОВО МЕСТО | Фармацевтическая композиция, содержащая тикагрелор |
CN110327305A (zh) * | 2019-06-26 | 2019-10-15 | 慧生医学科技(徐州)有限公司 | 一种替格瑞洛片及其制备方法 |
GR1010621B (el) * | 2022-12-19 | 2024-01-30 | Elpen Ανωνυμος Εταιρεια Φαρμακευτικη Βιομηχανια, | Στερεες φαρμακοτεχνικες μορφες τικαγρελορης |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US118410A (en) | 1871-08-22 | Improvement in combined hay and manure-forks | ||
US4721709A (en) | 1984-07-26 | 1988-01-26 | Pyare Seth | Novel pharmaceutical compositions containing hydrophobic practically water-insoluble drugs adsorbed on pharmaceutical excipients as carrier; process for their preparation and the use of said compositions |
AR017014A1 (es) | 1997-07-22 | 2001-08-22 | Astrazeneca Ab | Compuestos de triazolo [4,5-d]pirimidina, composiciones farmaceuticas, uso de los mismos para preparar medicamentos y procesos para la preparacionde dichos compuestos |
TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
UA74141C2 (ru) | 1998-12-09 | 2005-11-15 | Дж.Д. Сірл Енд Ко. | Фармацевтическая композиция на основе тонкодисперсного эплеренона (варианты), способ ее получения и способ лечения расстройств, опосредованных альдостероном (варианты) |
GB0013407D0 (en) | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
EP1313451B1 (en) * | 2000-08-31 | 2009-03-11 | Jagotec AG | Milled particles |
SE0101932D0 (sv) | 2001-05-31 | 2001-05-31 | Astrazeneca Ab | Pharmaceutical combinations |
UA80991C2 (en) | 2002-10-07 | 2007-11-26 | Solid preparation containing an insulin resistance improving drug and an active ingredient useful as a remedy for diabetes | |
SI1715893T1 (sl) | 2004-01-20 | 2009-12-31 | Novartis Pharma Ag | Direktna kompresijska formulacija in postopek |
KR20080016952A (ko) * | 2005-06-13 | 2008-02-22 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 클로피도그렐과 아스피린의 배합 제제 |
US20080214599A1 (en) * | 2005-08-19 | 2008-09-04 | John Thomas Brandt | Use of Par-1/Par-4 Inhibitors for Treating or Preventing Vascular Diseases |
CA2691214A1 (en) * | 2006-06-09 | 2007-12-21 | Kemia, Inc. | Therapy using cytokine inhibitors |
WO2008024044A1 (en) | 2006-08-21 | 2008-02-28 | Astrazeneca Ab | Compositions, suitable for oral administration, comprising a triazolo [4, 5] pyrimidin derivate |
TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
EP2591783A1 (en) * | 2007-04-13 | 2013-05-15 | Millennium Pharmaceuticals, Inc. | Combination anticoagulant therapy with a compound that acts as a factor Xa inhibitor |
EP2586439A1 (en) * | 2007-05-02 | 2013-05-01 | Portola Pharmaceuticals, Inc. | Combination therapy with a compound acting as a platelet ADP receptor inhibitor |
CN101795682A (zh) * | 2007-05-02 | 2010-08-04 | 波托拉医药品公司 | 直接起效和可逆的p2y12抑制剂的静脉内和口服给药 |
WO2009007675A2 (en) * | 2007-07-11 | 2009-01-15 | Cardoz Ab | Combination for use in the treatment of atherosclerosis comprising a mast cell inhibitor and a p2 gamma 12 antagonist |
BRPI0905717A2 (pt) * | 2008-01-11 | 2015-07-14 | Cipla Ltd | Composição farmacêutica, processo para preparar uma composição farmacêutica e forma de dosagem farmacêutica |
JP2011510024A (ja) | 2008-01-25 | 2011-03-31 | アルファファーム ピーティーワイ リミテッド | デュロキセチンの遅延放出医薬組成物 |
TR200801178A2 (tr) | 2008-02-22 | 2009-09-23 | Bi̇li̇m İlaç Sanayi̇ Ti̇caret A.Ş. | Nateglinid ve surfaktan-ph ayarlayıcı sistemi içeren oral tablet kompozisyonları |
DE102008037324A1 (de) | 2008-08-11 | 2010-02-18 | Ratiopharm Gmbh | Pharmazeutische Formulierung zur pulmonalen Blutdrucksenkung |
WO2010056910A2 (en) * | 2008-11-12 | 2010-05-20 | Carolus Therapeutics, Inc. | Methods of treating cardiovascular disorders |
EP2585161A1 (en) * | 2010-06-23 | 2013-05-01 | Stefan Kralev | Medical device for self-administration of patients with acute coronary events |
CN102657629B (zh) * | 2012-05-14 | 2014-04-02 | 深圳市华力康生物医药有限公司 | 替卡格雷缓释片系统及其制备方法 |
-
2010
- 2010-12-20 EP EP10795382.0A patent/EP2515871B1/en not_active Revoked
- 2010-12-20 EA EA201200937A patent/EA026094B1/ru not_active IP Right Cessation
- 2010-12-20 ES ES13169378.0T patent/ES2548845T3/es active Active
- 2010-12-20 US US13/518,450 patent/US8663661B2/en not_active Expired - Fee Related
- 2010-12-20 CA CA2785487A patent/CA2785487C/en not_active Expired - Fee Related
- 2010-12-20 WO PCT/EP2010/070268 patent/WO2011076749A2/en active Application Filing
- 2010-12-20 EP EP13169378.0A patent/EP2633857B1/en not_active Revoked
- 2010-12-20 ES ES10795382.0T patent/ES2550033T3/es active Active
-
2014
- 2014-01-29 US US14/167,490 patent/US20140147505A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
WO2011076749A2 (en) | 2011-06-30 |
WO2011076749A3 (en) | 2011-08-18 |
EP2515871B1 (en) | 2015-09-23 |
ES2550033T3 (es) | 2015-11-04 |
EP2633857A1 (en) | 2013-09-04 |
CA2785487C (en) | 2017-11-28 |
ES2548845T3 (es) | 2015-10-21 |
US20130028938A1 (en) | 2013-01-31 |
EP2633857B1 (en) | 2015-08-12 |
EP2515871A2 (en) | 2012-10-31 |
CA2785487A1 (en) | 2011-06-30 |
US20140147505A1 (en) | 2014-05-29 |
EA026094B1 (ru) | 2017-03-31 |
US8663661B2 (en) | 2014-03-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201200937A1 (ru) | Твердая лекарственная форма тикагрелора | |
UA106634C2 (ru) | Твердая фармацевтическая дозированная форма | |
MY163083A (en) | Solid forms of a pharmaceutically active substance | |
CR11709A (es) | Preparacion solida de desintegracion oral | |
MX2012012438A (es) | Formulaciones farmaceuticas que comprenden pioglitazona y linagliptina. | |
CY1119798T1 (el) | Μορφη iv υδροχλωρικης ιβαμπραδινης | |
ECSP13012467A (es) | Uso de aglutinantes para fabricar formulaciones estables al almacenamiento | |
EA201391087A1 (ru) | Оральные лекарственные формы препарата тазоцитиниба с модифицированным высвобождением | |
EA201291211A1 (ru) | Фармацевтические композиции, содержащие гидроморфон и налоксон | |
EA201390662A1 (ru) | Фармацевтическая композиция, содержащая дутастерид | |
IT1404931B1 (it) | Composizioni oftalmiche per la somministrazione di principi attivi liposolubili . | |
EA201590805A1 (ru) | Композиция с немедленным и пролонгированным высвобождением | |
MX344846B (es) | Combinacion de granulos cargados activos con activos adicionales. | |
PH12015500823A1 (en) | Modified release formulations for oprozomib | |
BR112012028788A2 (pt) | fabricação de grânulos sem ativos | |
MX343689B (es) | Formulaciones combinadas de darunavir. | |
TN2011000651A1 (en) | Solid pharmaceutical fixed dose compositions comprising irbesartan and amlodipine their preparation and their therapeutic application | |
EA201300034A1 (ru) | Фармацевтические композиции, содержащие иматиниб или его фармацевтически приемлемую соль, и способы их получения | |
EA201200616A1 (ru) | Производные 2-оксо-1-пирролидинилимидазотиадиазола | |
MX341976B (es) | Formulaciones de darunavir. | |
PH12014501408A1 (en) | Immediate release multi unit pellet system | |
EA201501164A1 (ru) | Твердая фармацевтическая лекарственная форма | |
MX363699B (es) | Producto de comicronizacion que comprende acetato de ulipristal. | |
EA201200485A1 (ru) | Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол | |
EA201490233A8 (ru) | Стабильные лекарственные формы артеролана и пиперахина |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG MD TJ TM RU |